1. Home
  2. ARMP vs LNSR Comparison

ARMP vs LNSR Comparison

Compare ARMP & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$6.42

Market Cap

125.7M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$12.35

Market Cap

136.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARMP
LNSR
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.7M
136.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARMP
LNSR
Price
$6.42
$12.35
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$12.00
$15.00
AVG Volume (30 Days)
54.2K
32.9K
Earning Date
03-19-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,054,000.00
$59,141,000.00
Revenue This Year
$4.48
$19.55
Revenue Next Year
N/A
$35.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.02
52 Week Low
$0.90
$8.96
52 Week High
$16.34
$17.31

Technical Indicators

Market Signals
Indicator
ARMP
LNSR
Relative Strength Index (RSI) 51.52 61.22
Support Level $5.75 $12.12
Resistance Level $6.37 $12.85
Average True Range (ATR) 0.74 0.32
MACD -0.02 0.05
Stochastic Oscillator 33.19 63.50

Price Performance

Historical Comparison
ARMP
LNSR

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Share on Social Networks: